CN111228297B - 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用 - Google Patents

岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用 Download PDF

Info

Publication number
CN111228297B
CN111228297B CN202010071273.0A CN202010071273A CN111228297B CN 111228297 B CN111228297 B CN 111228297B CN 202010071273 A CN202010071273 A CN 202010071273A CN 111228297 B CN111228297 B CN 111228297B
Authority
CN
China
Prior art keywords
ldl
foam cells
autophagy
fucoidan
sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010071273.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111228297A (zh
Inventor
宋淑亮
吉爱国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong University
Original Assignee
Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong University filed Critical Shandong University
Priority to CN202010071273.0A priority Critical patent/CN111228297B/zh
Priority to PCT/CN2020/079331 priority patent/WO2021147151A1/zh
Priority to KR1020217000140A priority patent/KR20210096588A/ko
Publication of CN111228297A publication Critical patent/CN111228297A/zh
Application granted granted Critical
Publication of CN111228297B publication Critical patent/CN111228297B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202010071273.0A 2020-01-21 2020-01-21 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用 Active CN111228297B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010071273.0A CN111228297B (zh) 2020-01-21 2020-01-21 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用
PCT/CN2020/079331 WO2021147151A1 (zh) 2020-01-21 2020-03-13 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用
KR1020217000140A KR20210096588A (ko) 2020-01-21 2020-03-13 ox-LDL의 분해를 위한 거품세포의 자가포식 촉진에서 푸코산 설페이트의 응용

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010071273.0A CN111228297B (zh) 2020-01-21 2020-01-21 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用

Publications (2)

Publication Number Publication Date
CN111228297A CN111228297A (zh) 2020-06-05
CN111228297B true CN111228297B (zh) 2021-03-19

Family

ID=70874881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010071273.0A Active CN111228297B (zh) 2020-01-21 2020-01-21 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用

Country Status (3)

Country Link
KR (1) KR20210096588A (ko)
CN (1) CN111228297B (ko)
WO (1) WO2021147151A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559114B (zh) * 2021-09-26 2022-01-18 汇泰渤海水产有限责任公司 浒苔多糖在降低泡沫细胞脂质堆积中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094561A1 (en) * 2008-01-24 2009-07-30 The Government Of The United States Of America As Represented By The Secretary Of The Departmentof Induced internalization of surface receptors
CN104586878A (zh) * 2015-01-14 2015-05-06 青岛海洋生物医药研究院股份有限公司 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用
CN105399848A (zh) * 2015-11-20 2016-03-16 中国科学院上海药物研究所 一种岩藻聚糖硫酸酯、其制备方法和用途
CN107011454A (zh) * 2017-04-10 2017-08-04 浙江海洋大学 一种低分子量高硫酸化的海参岩藻聚糖硫酸酯制备方法
CN109432121A (zh) * 2018-11-22 2019-03-08 复旦大学 岩藻聚糖在抑制lox-1信号途径中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015351A1 (en) * 2017-07-14 2019-01-17 Drexel University Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis
CN108014086A (zh) * 2017-12-26 2018-05-11 中国科学院海洋研究所 一种褐藻多糖硫酸酯胶囊的制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094561A1 (en) * 2008-01-24 2009-07-30 The Government Of The United States Of America As Represented By The Secretary Of The Departmentof Induced internalization of surface receptors
CN104586878A (zh) * 2015-01-14 2015-05-06 青岛海洋生物医药研究院股份有限公司 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用
CN105399848A (zh) * 2015-11-20 2016-03-16 中国科学院上海药物研究所 一种岩藻聚糖硫酸酯、其制备方法和用途
CN107011454A (zh) * 2017-04-10 2017-08-04 浙江海洋大学 一种低分子量高硫酸化的海参岩藻聚糖硫酸酯制备方法
CN109432121A (zh) * 2018-11-22 2019-03-08 复旦大学 岩藻聚糖在抑制lox-1信号途径中的应用

Also Published As

Publication number Publication date
KR20210096588A (ko) 2021-08-05
CN111228297A (zh) 2020-06-05
WO2021147151A1 (zh) 2021-07-29

Similar Documents

Publication Publication Date Title
EP0702551B1 (en) Compositions and methods for reparation and prevention of fibrotic lesions
Gibson et al. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study
Fresco et al. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo‐controlled, double‐blind, multicenter clinical trial
Gutman et al. Effects of adrenocorticotropic hormone (ACTH) in gout
US20090035292A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
CN111228297B (zh) 岩藻聚糖硫酸酯在促进泡沫细胞自噬分解ox-LDL中的应用
WO2007143930A1 (fr) Utilisation de 20(s)-protopanoxadiol dans la fabrication d'antidépresseurs
Santus et al. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol
Bozic et al. The role of quinidine in the pharmacological therapy of ventricular arrhythmias ‘quinidine’
CN102065857A (zh) 决奈达隆或其可药用盐在制备用于调节血钾水平的药物中的用途
Fan et al. Magnesium isoglycyrrhizinate ameliorates concanavalin A-induced liver injury by inhibiting autophagy
Tomasoni et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
Riccioni et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature
CN112807297A (zh) 6-重氮-5-氧代-l-正亮氨酸在制备防治银屑病药物中的应用
Cai et al. Sulfated glucuronomannan hexasaccharide G6S1 enhanced lipolysis and lipophagy via PPARα pathway
Shiga et al. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia
McNamara et al. PS1460 LONG‐TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL
Latini et al. Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial
Xin et al. Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway.
Huntgeburth et al. Hypereosinophilic syndrome associated with acute necrotizing myocarditis and cardiomyopathy
TW202011958A (zh) Ｅｚｈ２負調節劑用於治療致密化不全心肌症的用途
RU2188644C2 (ru) Способ лечения туберкулеза легких
Isenberg 02 Debate: a majority of lupus patients (will) need a biologic!
Jia et al. CARDIOPROTECTIVE EFFECTS OF GRANULOCYTE COLONY‐STIMULATING FACTOR IN ANGIOTENSIN II‐INDUCED CARDIAC REMODELLING
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant